Insights into cardio-oncology:Polypharmacology of quinazoline-based α1-adrenoceptor antagonists  

作　　者：Salvatore Patanè 

机构地区：[1]Cardiologia Ospedale San Vincenzo,Taormina(Me) Azienda Sanitaria Provinciale di Messina,98039 Taormina,Messina,Italy

出　　处：《World Journal of Cardiology》2015年第5期238-242,共5页世界心脏病学杂志（英文版）（电子版）

摘　　要：New uses of cardiovascular drugs with proven experience are emerging,including for treating cancer.Quinazoline is a compound made up of two fused six member simple aromatic rings,benzene and pyrimidine rings,with several biological effects.Cardiologists first used quinazoline-based α1-adrenoceptor antagonists prazosin,doxazosin,and terazosin; currently available data support their use as safe,well tolerated,and effective add-on therapy in uncontrolled hypertension with additional favourable metabolic effects.Recent findings highlight the anticancer effects of quinazoline-based α1-adrenoceptor antagonists,indicating that they may have a significant role in uncontrolled hypertensive cancer patients without signs of ischemia.New uses of cardiovascular drugs with proven experience are emerging,including for treating cancer.Quinazoline is a compound made up of two fused six member simple aromatic rings,benzene and pyrimidine rings,with several biological effects.Cardiologists first used quinazoline-based α1-adrenoceptor antagonists prazosin,doxazosin,and terazosin; currently available data support their use as safe,well tolerated,and effective add-on therapy in uncontrolled hypertension with additional favourable metabolic effects.Recent findings highlight the anticancer effects of quinazoline-based α1-adrenoceptor antagonists,indicating that they may have a significant role in uncontrolled hypertensive cancer patients without signs of ischemia.

关 键 词：Cardio-oncology Multidrug resistance PRAZOSIN TERAZOSIN Doxazosin 

分 类 号：R732.1[医药卫生—肿瘤]